- Home
- HHS vs RLYB Comparison
HHS vs RLYB Comparison
Compare HHS & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- RLYB
- Stock Information
- Founded
- HHS 1923
- RLYB 2018
- Country
- HHS United States
- RLYB United States
- Employees
- HHS N/A
- RLYB N/A
- Industry
- HHS Advertising
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- RLYB Health Care
- Exchange
- HHS Nasdaq
- RLYB Nasdaq
- Market Cap
- HHS 55.0M
- RLYB 46.1M
- IPO Year
- HHS N/A
- RLYB 2021
- Fundamental
- Price
- HHS $7.27
- RLYB $1.11
- Analyst Decision
- HHS
- RLYB Buy
- Analyst Count
- HHS 0
- RLYB 6
- Target Price
- HHS N/A
- RLYB $8.30
- AVG Volume (30 Days)
- HHS 16.2K
- RLYB 47.2K
- Earning Date
- HHS 11-07-2024
- RLYB 11-07-2024
- Dividend Yield
- HHS N/A
- RLYB N/A
- EPS Growth
- HHS N/A
- RLYB N/A
- EPS
- HHS N/A
- RLYB N/A
- Revenue
- HHS $187,093,000.00
- RLYB $299,000.00
- Revenue This Year
- HHS N/A
- RLYB N/A
- Revenue Next Year
- HHS $4.05
- RLYB N/A
- P/E Ratio
- HHS N/A
- RLYB N/A
- Revenue Growth
- HHS N/A
- RLYB N/A
- 52 Week Low
- HHS $5.39
- RLYB $1.08
- 52 Week High
- HHS $8.87
- RLYB $4.60
- Technical
- Relative Strength Index (RSI)
- HHS 44.49
- RLYB 47.50
- Support Level
- HHS $6.66
- RLYB $1.09
- Resistance Level
- HHS $7.41
- RLYB $1.18
- Average True Range (ATR)
- HHS 0.25
- RLYB 0.04
- MACD
- HHS -0.03
- RLYB 0.00
- Stochastic Oscillator
- HHS 55.66
- RLYB 22.22
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.